SEC Form 4 · accession 0000899243-17-028850
Spero Therapeutics, Inc. · SPRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joel Sendek
Officer — Chief Financial Officer
Period of report
Dec 13, 2017
Accepted (ET)
Dec 15, 2017 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001701108
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.63 | Dec 13, 2017 | A | 27,795 | A | — | Dec 12, 2027 | Common Stock | 27,795 | 27,795 | D |
Explanation of responses
- F1The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.